254 related articles for article (PubMed ID: 10918072)
1. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping.
Smith AJ; van Helvoort A; van Meer G; Szabo K; Welker E; Szakacs G; Varadi A; Sarkadi B; Borst P
J Biol Chem; 2000 Aug; 275(31):23530-9. PubMed ID: 10918072
[TBL] [Abstract][Full Text] [Related]
2. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine.
van Helvoort A; Smith AJ; Sprong H; Fritzsche I; Schinkel AH; Borst P; van Meer G
Cell; 1996 Nov; 87(3):507-17. PubMed ID: 8898203
[TBL] [Abstract][Full Text] [Related]
3. Transport of phosphatidylcholine in MDR3-negative epithelial cell lines via drug-induced MDR1 P-glycoprotein.
Abulrob AG; Gumbleton M
Biochem Biophys Res Commun; 1999 Aug; 262(1):121-6. PubMed ID: 10448079
[TBL] [Abstract][Full Text] [Related]
4. Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia.
Horio M; Chin KV; Currier SJ; Goldenberg S; Williams C; Pastan I; Gottesman MM; Handler J
J Biol Chem; 1989 Sep; 264(25):14880-4. PubMed ID: 2570070
[TBL] [Abstract][Full Text] [Related]
5. Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil.
Kakumoto M; Sakaeda T; Takara K; Nakamura T; Kita T; Yagami T; Kobayashi H; Okamura N; Okumura K
Cancer Sci; 2003 Jan; 94(1):81-6. PubMed ID: 12708479
[TBL] [Abstract][Full Text] [Related]
6. Differential Coupling of Binding, ATP Hydrolysis, and Transport of Fluorescent Probes with P-Glycoprotein in Lipid Nanodiscs.
Li MJ; Nath A; Atkins WM
Biochemistry; 2017 May; 56(19):2506-2517. PubMed ID: 28441502
[TBL] [Abstract][Full Text] [Related]
7. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P
Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401
[TBL] [Abstract][Full Text] [Related]
8. ATPase activity of nucleotide binding domains of human MDR3 in the context of MDR1.
Ishigami M; Tominaga Y; Nagao K; Kimura Y; Matsuo M; Kioka N; Ueda K
Biochim Biophys Acta; 2013 Apr; 1831(4):683-90. PubMed ID: 23305784
[TBL] [Abstract][Full Text] [Related]
9. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1.
Takeuchi T; Yoshitomi S; Higuchi T; Ikemoto K; Niwa S; Ebihara T; Katoh M; Yokoi T; Asahi S
Pharm Res; 2006 Jul; 23(7):1460-72. PubMed ID: 16779700
[TBL] [Abstract][Full Text] [Related]
10. Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport.
Takara K; Sakaeda T; Kakumoto M; Tanigawara Y; Kobayashi H; Okumura K; Ohnishi N; Yokoyama T
Oncol Res; 2009; 17(11-12):527-33. PubMed ID: 19806783
[TBL] [Abstract][Full Text] [Related]
11. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier.
Luker GD; Rao VV; Crankshaw CL; Dahlheimer J; Piwnica-Worms D
Biochemistry; 1997 Nov; 36(46):14218-27. PubMed ID: 9369495
[TBL] [Abstract][Full Text] [Related]
12. ABC transporters in lipid transport.
Borst P; Zelcer N; van Helvoort A
Biochim Biophys Acta; 2000 Jun; 1486(1):128-44. PubMed ID: 10856718
[TBL] [Abstract][Full Text] [Related]
13. Domain exchangeability between the multidrug transporter (MDR1) and phosphatidylcholine flippase (MDR2).
Zhou Y; Gottesman MM; Pastan I
Mol Pharmacol; 1999 Nov; 56(5):997-1004. PubMed ID: 10531406
[TBL] [Abstract][Full Text] [Related]
14. Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites.
Urbatsch IL; Beaudet L; Carrier I; Gros P
Biochemistry; 1998 Mar; 37(13):4592-602. PubMed ID: 9521779
[TBL] [Abstract][Full Text] [Related]
15. Xenobiotic transport differences in mouse mesangial cell clones expressing mdr1 and mdr3.
Ernest S; Bello-Reuss E
Am J Physiol; 1996 Mar; 270(3 Pt 1):C910-9. PubMed ID: 8638674
[TBL] [Abstract][Full Text] [Related]
16. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
17. Phospholipid flippase activity of the reconstituted P-glycoprotein multidrug transporter.
Romsicki Y; Sharom FJ
Biochemistry; 2001 Jun; 40(23):6937-47. PubMed ID: 11389609
[TBL] [Abstract][Full Text] [Related]
18. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin.
Chen WS; Luker KE; Dahlheimer JL; Pica CM; Luker GD; Piwnica-Worms D
Biochem Pharmacol; 2000 Aug; 60(3):413-26. PubMed ID: 10856437
[TBL] [Abstract][Full Text] [Related]
19. Studies of human MDR1-MDR2 chimeras demonstrate the functional exchangeability of a major transmembrane segment of the multidrug transporter and phosphatidylcholine flippase.
Zhou Y; Gottesman MM; Pastan I
Mol Cell Biol; 1999 Feb; 19(2):1450-9. PubMed ID: 9891078
[TBL] [Abstract][Full Text] [Related]
20. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
